AHT-102

AHT-102 is a recombinant humanized bifunctional fusion protein consisting of a monoclonal antibody targeting programmed cell death 1 ligand 1 (PD-L1) fused to the extracellular domain of the transforming growth factor-beta receptor type II (TGF-βRII). Developed by Guangxi Lugang Biopharmaceutical Technology, AHT-102 is designed to simultaneously inhibit two major immunosuppressive pathways within the tumor microenvironment: the PD-1/PD-L1 checkpoint and TGF-β signaling. By blocking PD-L1, the drug restores T-cell activation and anti-tumor immunity, while the TGF-β trap component neutralizes TGF-β to reduce fibrosis and alleviate immune exclusion. This dual mechanism aims to overcome resistance to traditional checkpoint inhibitors and is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors.